News

“Bold, clinically-led changes” to how NHS services are delivered must be instilled over the next couple of years to address a funding gap that could hit a whopping £30 billion over the next few years, NHS England has warned.

The National Institute for Health and Care Excellence (NICE) has issued new draft guidance not recommending Celgene’s Revlimid (lenalidomide) for the treatment of myelodysplastic syndromes (MDS), but has also opened a public consultation on this preliminary decision.

A business-discovery platform that consolidates data from multiple sources into a single application for analysis is helping the National Institute for Health Research’s Clinical Research Network (NIHR CRN) to improve the performance of its supported studies.

Roche has terminated development of aleglitazar due to safety concerns about the late-stage diabetes treatment.

Cost regulators for NHS Scotland have given children with Crohn’s disease routine access to AbbVie’s Humira, marking the first of the UK nations to accept the drug’s use in this setting.

Theorem Clinical Research, the US-based provider of clinical research and development services, has boosted its resources in regulatory consulting and medical devices/diagnostics through a strategic partnership with Emergo Group.

Vifor Pharma has published findings from a major study which shows that its intravenous treatment Ferinject significantly prolongs the time until other anaemia treatment is needed.

The University of Manchester and the city’s specialist cancer centre, the Christie NHS Foundation Trust, are putting £30 million into a recruitment drive for academic researchers and their teams to support the Manchester Cancer Research Centre (MCRC).

ALK-Abello’s experimental house dust mite allergy pill remains on track for a 2014 filing, after a second Phase III trial assessing its safety and efficacy achieved its targets.

The European Union (EU) has been urged to act swiftly to deal with the “dreadful” situation faced by millions of people in terms of access to medicines, so that “a public health disaster” can be avoided.

Ahead of its plans to relocate part of its R&D operations to Cambridge, AstraZeneca has signed up to three cancer projects in the UK city.

The European Union/industry Innovative Medicines Initiative (IMI) has launched its ninth call for proposals, with a total budget of 135 million euros and a focus on age-related conditions, tapping into social media to monitor drug safety and advances in antibiotics.

Johnson & Johnson and Pharmacyclics have submitted their ‘breakthrough’ blood cancer drug ibrutinib to the US Food and Drug Administration for approval.

Omthera Pharmaceuticals, which is in the process of being acquired by AstraZeneca, has filed its anti-triglyceride drug Epanova with regulators in the USA.

Otsuka Pharmaceutical Co says that enrollment has begun for “a ground-breaking clinical programme” looking at its investigational drug delamanid for paediatric multidrug-resistant tuberculosis (MDR-TB).